<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640224</url>
  </required_header>
  <id_info>
    <org_study_id>0503013</org_study_id>
    <secondary_id>2K24HD001357</secondary_id>
    <nct_id>NCT00640224</nct_id>
  </id_info>
  <brief_title>Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study</brief_title>
  <official_title>Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS: Effects of Insulin Sensitizers Versus Oral Contraceptives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silva Arslanian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to investigate the effects of 2 different treatments (drospirenone/ethinyl
      estradiol versus rosiglitazone) on insulin sensitivity and androgen levels, inflammatory
      markers, vascular markers and bone development in overweight adolescent females with
      polycystic ovary syndrome (PCOS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to:

      1) to compare effects of treatment with drospirenone/ethinyl estradiol (Yasmin)versus
      rosiglitazone (Avandia) on hyperandrogenism, insulin resistance/hyperinsulinemia, adrenal
      hyperresponsiveness, body composition, chronic inflammation, bone mass and turnover.

      OCPs are the first-line therapy for PCOS, however, they do not address the insulin resistance
      or the inflammation. Insulin sensitizers have been used successfully to treat PCOS but
      thiazolidinediones such as rosiglitazone have not been used in adolescents. Therefore we will
      investigate the effects of treatment with drospirenone/ethinyl estradiol versus rosiglitazone
      in overweight adolescents with PCOS. We will obtain comprehensive evaluations before and 6
      months after randomization, to the respective treatment arms to determine the differences
      between the 2 treatment modalities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral Insulin Sensitivity at Baseline and 6 Months.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Peripheral insulin sensitivity was evaluated during the hyperinsulinemic-euglycemic clamp.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Insulin Sensitivity at Baseline and 6 Months.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Hepatic insulin sensitivity was evaluated prior to the hyperinsulinemic-euglycemic clamp.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Tolerance Status at Baseline and 6 Months.</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Glucose tolerance status was classified according to the ADA (American Diabetes Association) criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Fat Mass at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>DXA (dual-energy x-ray absorptiometry) scans were done to measure total fat mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Testosterone at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Total testosterone was measured by HPLC(high-performance liquid chromatography)-tandem mass spectroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Body Fat at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>DXA scans were done to measure the percentage of body fat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Testosterone at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Free testosterone was measured by equilibrium dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SHBG at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>SHBG (sex hormone-binding globulin) was measured by immunoradiometric assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DHEAS at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>DHEAS (dehydroepiandrosterone sulfate) was measured by radioimmunoassay in dilute serum after hydrolysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta Androstenedione at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Delta Androstenedione was measured by HPLC-tandem mass spectroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta DHEA at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Delta DHEA was measured by HPLC-tandem mass spectroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta 17-OHProg at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Delta 17-OHProg (17-hydroxyprogesterone) was measured by HPLC-tandem mass spectroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta 17-OHPreg at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Delta 17-OHPreg (17-hydroxypregnenolone) was measured by HPLC-tandem mass spectroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Cholesterol was measured using the standards of the Centers for Disease Control and Prevention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>HDL (high-density lipoprotein) was measured using the standards of the Centers for Disease Control and Prevention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>LDL (low-density lipoprotein) was measured using the standards of the Centers for Disease Control and Prevention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Triglycerides were measured using the standards of the Centers for Disease Control and Prevention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-HDL Cholesterol at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Non-HDL cholesterol was measured using the standards of the Centers for Disease Control and Prevention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Adiponectin was measured by radioimmunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Leptin was measured by radioimmunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hs-CRP at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>hs-CRP(high-sensitivity C-reactive protein) was measured by COAG-Nephelometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Blood Pressure at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Morning blood pressure was measured with an automated sphygmomanometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Blood Pressure at Baseline and 6 Months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Night blood pressure was measured with an automated sphygmomanometer.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drospirenone/ethinyl estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight/Obese without PCOS</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes. *No participants were enrolled in this Arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean without PCOS</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers. *No participants were enrolled in this Arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
    <description>4 mg daily for 6 months</description>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drospirenone/ethinyl estradiol</intervention_name>
    <description>1 tab (3mg/30mcg) daily for 6 months</description>
    <arm_group_label>Drospirenone/ethinyl estradiol</arm_group_label>
    <other_name>Yasmin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 10 - 20 years

          -  Pubertal level of Tanner stage III-V and menarchal

          -  BMI percentile for age and sex greater than or equal to 85%ile

        Exclusion Criteria:

          -  Oral medications for PCOS, or that have impact on bone (i.e. anti-epileptics)

          -  Presence of other diseases, systemic or psychiatric, or chronic medications which
             could interfere with endocrine function

          -  Established diagnosis of diabetes

          -  Prior bone surgery, prior osteoporotic fracture, or fracture in the past 12 months

          -  Prior thromboembolic event, such as a deep venous thrombosis or pulmonary embolism
             (PCOS subjects only)

          -  Vitamin D deficiency (&lt;10ng/mL)

          -  Hyperkalemia (K&gt;5.0 meq/L)

          -  Positive pregnancy test (serum)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silva Arslanian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tfayli H, Ulnach JW, Lee S, Sutton-Tyrrell K, Arslanian S. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors. J Clin Endocrinol Metab. 2011 May;96(5):1311-9. doi: 10.1210/jc.2010-2547. Epub 2011 Feb 16.</citation>
    <PMID>21325466</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <results_first_submitted>July 27, 2017</results_first_submitted>
  <results_first_submitted_qc>October 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2017</results_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Silva Arslanian</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overweight/obese patients with PCOS were recruited from the Children’s Hospital of Pittsburgh (CHP) PCOS center and the community through advertisements and flyers posted in the medical campus and in pediatricians’ offices.</recruitment_details>
      <pre_assignment_details>9 did not meet diagnostic criteria, 3 were on psychiatric meds,1 was diagnosed with diabetes,1 had venous access issues, and 5 did not complete baseline evaluations. No participants were enrolled in the &quot;Overweight/Obese without PCOS&quot; or &quot;Lean without PCOS&quot; Arms/Groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosiglitazone</title>
          <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Drospirenone/Ethinyl Estradiol</title>
          <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
        </group>
        <group group_id="P3">
          <title>Overweight/Obese Without PCOS</title>
          <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
        </group>
        <group group_id="P4">
          <title>Lean Without PCOS</title>
          <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Headaches</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosiglitazone</title>
          <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Drospirenone/Ethinyl Estradiol</title>
          <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Overweight/Obese Without PCOS</title>
          <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
        </group>
        <group group_id="B4">
          <title>Lean Without PCOS</title>
          <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.7" spread="4.1"/>
                    <measurement group_id="B2" value="16.2" spread="4.5"/>
                    <measurement group_id="B5" value="16.0" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peripheral Insulin Sensitivity at Baseline and 6 Months.</title>
        <description>Peripheral insulin sensitivity was evaluated during the hyperinsulinemic-euglycemic clamp.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Peripheral Insulin Sensitivity at Baseline and 6 Months.</title>
          <description>Peripheral insulin sensitivity was evaluated during the hyperinsulinemic-euglycemic clamp.</description>
          <units>mg/kg/min per uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peripheral insulin sensitivity, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.2"/>
                    <measurement group_id="O2" value="2.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral insulin sensitivity, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.4"/>
                    <measurement group_id="O2" value="2.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hepatic Insulin Sensitivity at Baseline and 6 Months.</title>
        <description>Hepatic insulin sensitivity was evaluated prior to the hyperinsulinemic-euglycemic clamp.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Insulin Sensitivity at Baseline and 6 Months.</title>
          <description>Hepatic insulin sensitivity was evaluated prior to the hyperinsulinemic-euglycemic clamp.</description>
          <units>(mg/kg/min x uU/mL)-1</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hepatic insulin sensitivity, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="1.8"/>
                    <measurement group_id="O2" value="17.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic insulin sensitivity, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="3.4"/>
                    <measurement group_id="O2" value="16.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucose Tolerance Status at Baseline and 6 Months.</title>
        <description>Glucose tolerance status was classified according to the ADA (American Diabetes Association) criteria.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tolerance Status at Baseline and 6 Months.</title>
          <description>Glucose tolerance status was classified according to the ADA (American Diabetes Association) criteria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal glucose tolerance, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impaired glucose tolerance, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal glucose tolerance, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impaired glucose tolerance, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fat Mass at Baseline and 6 Months</title>
        <description>DXA (dual-energy x-ray absorptiometry) scans were done to measure total fat mass.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fat Mass at Baseline and 6 Months</title>
          <description>DXA (dual-energy x-ray absorptiometry) scans were done to measure total fat mass.</description>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fat mass, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="2.8"/>
                    <measurement group_id="O2" value="48.0" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fat mass, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" spread="3.4"/>
                    <measurement group_id="O2" value="49.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Testosterone at Baseline and 6 Months</title>
        <description>Total testosterone was measured by HPLC(high-performance liquid chromatography)-tandem mass spectroscopy.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Total Testosterone at Baseline and 6 Months</title>
          <description>Total testosterone was measured by HPLC(high-performance liquid chromatography)-tandem mass spectroscopy.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Testosterone, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7" spread="5.6"/>
                    <measurement group_id="O2" value="34.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Testosterone, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="3.7"/>
                    <measurement group_id="O2" value="30.6" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Body Fat at Baseline and 6 Months</title>
        <description>DXA scans were done to measure the percentage of body fat.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Body Fat at Baseline and 6 Months</title>
          <description>DXA scans were done to measure the percentage of body fat.</description>
          <units>percentage of body fat</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent body fat, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="1.1"/>
                    <measurement group_id="O2" value="47.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent body fat, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6" spread="1.6"/>
                    <measurement group_id="O2" value="48.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Testosterone at Baseline and 6 Months</title>
        <description>Free testosterone was measured by equilibrium dialysis.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Free Testosterone at Baseline and 6 Months</title>
          <description>Free testosterone was measured by equilibrium dialysis.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Free Testosterone, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="2.0"/>
                    <measurement group_id="O2" value="7.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free Testosterone, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="1.6"/>
                    <measurement group_id="O2" value="1.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SHBG at Baseline and 6 Months</title>
        <description>SHBG (sex hormone-binding globulin) was measured by immunoradiometric assay.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>SHBG at Baseline and 6 Months</title>
          <description>SHBG (sex hormone-binding globulin) was measured by immunoradiometric assay.</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SHBG, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="4.6"/>
                    <measurement group_id="O2" value="22.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SHBG, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="6.6"/>
                    <measurement group_id="O2" value="154.5" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DHEAS at Baseline and 6 Months</title>
        <description>DHEAS (dehydroepiandrosterone sulfate) was measured by radioimmunoassay in dilute serum after hydrolysis.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>DHEAS at Baseline and 6 Months</title>
          <description>DHEAS (dehydroepiandrosterone sulfate) was measured by radioimmunoassay in dilute serum after hydrolysis.</description>
          <units>ug/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DHEAS, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.4" spread="17.0"/>
                    <measurement group_id="O2" value="212.2" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DHEAS, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.9" spread="17.9"/>
                    <measurement group_id="O2" value="197.5" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta Androstenedione at Baseline and 6 Months</title>
        <description>Delta Androstenedione was measured by HPLC-tandem mass spectroscopy.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Androstenedione at Baseline and 6 Months</title>
          <description>Delta Androstenedione was measured by HPLC-tandem mass spectroscopy.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Delta Androstenedione, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="11.5"/>
                    <measurement group_id="O2" value="82.6" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delta Androstenedione, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" spread="9.5"/>
                    <measurement group_id="O2" value="117.0" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta DHEA at Baseline and 6 Months</title>
        <description>Delta DHEA was measured by HPLC-tandem mass spectroscopy.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Delta DHEA at Baseline and 6 Months</title>
          <description>Delta DHEA was measured by HPLC-tandem mass spectroscopy.</description>
          <units>ug/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Delta DHEA, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="817.4" spread="119.5"/>
                    <measurement group_id="O2" value="1001.6" spread="183.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delta DHEA, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="643.4" spread="102.4"/>
                    <measurement group_id="O2" value="1092.1" spread="188.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta 17-OHProg at Baseline and 6 Months</title>
        <description>Delta 17-OHProg (17-hydroxyprogesterone) was measured by HPLC-tandem mass spectroscopy.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Delta 17-OHProg at Baseline and 6 Months</title>
          <description>Delta 17-OHProg (17-hydroxyprogesterone) was measured by HPLC-tandem mass spectroscopy.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Delta 17-OHProg, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.0" spread="37.4"/>
                    <measurement group_id="O2" value="169.8" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delta 17-OHProg, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.0" spread="49.1"/>
                    <measurement group_id="O2" value="175.4" spread="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delta 17-OHPreg at Baseline and 6 Months</title>
        <description>Delta 17-OHPreg (17-hydroxypregnenolone) was measured by HPLC-tandem mass spectroscopy.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Delta 17-OHPreg at Baseline and 6 Months</title>
          <description>Delta 17-OHPreg (17-hydroxypregnenolone) was measured by HPLC-tandem mass spectroscopy.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Delta 17-OHPreg, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="912.8" spread="92.1"/>
                    <measurement group_id="O2" value="1024.3" spread="114.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delta 17-OHPreg, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="914.7" spread="110.9"/>
                    <measurement group_id="O2" value="1088.9" spread="161.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cholesterol at Baseline and 6 Months</title>
        <description>Cholesterol was measured using the standards of the Centers for Disease Control and Prevention.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol at Baseline and 6 Months</title>
          <description>Cholesterol was measured using the standards of the Centers for Disease Control and Prevention.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149.5" spread="8.1"/>
                    <measurement group_id="O2" value="156.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.2" spread="7.9"/>
                    <measurement group_id="O2" value="185.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL at Baseline and 6 Months</title>
        <description>HDL (high-density lipoprotein) was measured using the standards of the Centers for Disease Control and Prevention.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>HDL at Baseline and 6 Months</title>
          <description>HDL (high-density lipoprotein) was measured using the standards of the Centers for Disease Control and Prevention.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="3.0"/>
                    <measurement group_id="O2" value="40.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" spread="2.1"/>
                    <measurement group_id="O2" value="55.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL at Baseline and 6 Months</title>
        <description>LDL (low-density lipoprotein) was measured using the standards of the Centers for Disease Control and Prevention.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>LDL at Baseline and 6 Months</title>
          <description>LDL (low-density lipoprotein) was measured using the standards of the Centers for Disease Control and Prevention.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" spread="7.6"/>
                    <measurement group_id="O2" value="85.9" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3" spread="7.5"/>
                    <measurement group_id="O2" value="97.7" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides at Baseline and 6 Months</title>
        <description>Triglycerides were measured using the standards of the Centers for Disease Control and Prevention.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides at Baseline and 6 Months</title>
          <description>Triglycerides were measured using the standards of the Centers for Disease Control and Prevention.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Triglycerides, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.7" spread="8.1"/>
                    <measurement group_id="O2" value="148.4" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="6.3"/>
                    <measurement group_id="O2" value="163.5" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-HDL Cholesterol at Baseline and 6 Months</title>
        <description>Non-HDL cholesterol was measured using the standards of the Centers for Disease Control and Prevention.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Non-HDL Cholesterol at Baseline and 6 Months</title>
          <description>Non-HDL cholesterol was measured using the standards of the Centers for Disease Control and Prevention.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-HDL cholesterol, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="2.0"/>
                    <measurement group_id="O2" value="70.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL cholesterol, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" spread="1.9"/>
                    <measurement group_id="O2" value="87.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adiponectin at Baseline and 6 Months</title>
        <description>Adiponectin was measured by radioimmunoassay.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Adiponectin at Baseline and 6 Months</title>
          <description>Adiponectin was measured by radioimmunoassay.</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adiponectin, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="0.7"/>
                    <measurement group_id="O2" value="5.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adiponectin, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="1.2"/>
                    <measurement group_id="O2" value="6.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leptin at Baseline and 6 Months</title>
        <description>Leptin was measured by radioimmunoassay.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Leptin at Baseline and 6 Months</title>
          <description>Leptin was measured by radioimmunoassay.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leptin, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="4.6"/>
                    <measurement group_id="O2" value="40.6" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leptin, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" spread="4.9"/>
                    <measurement group_id="O2" value="46.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hs-CRP at Baseline and 6 Months</title>
        <description>hs-CRP(high-sensitivity C-reactive protein) was measured by COAG-Nephelometry.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Hs-CRP at Baseline and 6 Months</title>
          <description>hs-CRP(high-sensitivity C-reactive protein) was measured by COAG-Nephelometry.</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hs-CRP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.6"/>
                    <measurement group_id="O2" value="1.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hs-CRP, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.0"/>
                    <measurement group_id="O2" value="3.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Blood Pressure at Baseline and 6 Months</title>
        <description>Morning blood pressure was measured with an automated sphygmomanometer.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Blood Pressure at Baseline and 6 Months</title>
          <description>Morning blood pressure was measured with an automated sphygmomanometer.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning Systolic BP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.2" spread="2.6"/>
                    <measurement group_id="O2" value="108.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning Diasytolic BP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" spread="2.0"/>
                    <measurement group_id="O2" value="58.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning Systolic BP, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.5" spread="2.7"/>
                    <measurement group_id="O2" value="112.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning Diastolic BP, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="1.2"/>
                    <measurement group_id="O2" value="59.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Blood Pressure at Baseline and 6 Months</title>
        <description>Night blood pressure was measured with an automated sphygmomanometer.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone/Ethinyl Estradiol</title>
            <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
          </group>
          <group group_id="O3">
            <title>Overweight/Obese Without PCOS</title>
            <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
          </group>
          <group group_id="O4">
            <title>Lean Without PCOS</title>
            <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
          </group>
        </group_list>
        <measure>
          <title>Night Blood Pressure at Baseline and 6 Months</title>
          <description>Night blood pressure was measured with an automated sphygmomanometer.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Night Systolic BP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.5" spread="2.8"/>
                    <measurement group_id="O2" value="112.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Night Diastolic BP, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="1.5"/>
                    <measurement group_id="O2" value="58.6" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Night Systolic BP, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.2" spread="2.5"/>
                    <measurement group_id="O2" value="116.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Night Diastolic BP, 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="1.5"/>
                    <measurement group_id="O2" value="62.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosiglitazone</title>
          <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
rosiglitazone: 4 mg daily for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Drospirenone/Ethinyl Estradiol</title>
          <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
drospirenone/ethinyl estradiol: 1 tab (3mg/30mcg) daily for 6 months</description>
        </group>
        <group group_id="E3">
          <title>Overweight/Obese Without PCOS</title>
          <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
        </group>
        <group group_id="E4">
          <title>Lean Without PCOS</title>
          <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The potential unblinding due to the rapid regulation of withdrawal bleeding which may have influenced the dropout rates;the short duration of treatment in contrast to clinical practice where treatment may be for several years.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Silva Arslanian</name_or_title>
      <organization>Children's Hospital of Pittsburgh of UPMC</organization>
      <phone>412-692-6935</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

